Rapid advances in disease-modifying therapies (DMTs) for epilepsy, including gene-based therapies, anti-sense oligonucleotides, and stem cell-derived approaches are reshaping the treatment landscape. As these therapies move through clinical trials and toward regulatory review, they introduce complex clinical, operational, ethical, and equity considerations that extend well beyond traditional anti-seizure medication management.
Successful integration requires careful attention to patient selection, genetic and biomarker testing, multidisciplinary care models, infrastructure readiness, referral pathways, long-term safety monitoring, informed consent for novel and potentially irreversible interventions, access to clinical trials, and cost and reimbursement challenges. Significant investments in personnel, systems, and facilities may be necessary, raising important questions about implementation across diverse practice settings and the risk of widening disparities in care. In response, the American Epilepsy Society established the Disease-Modifying Therapies in Epilepsy Task Force to develop practical, evidence-informed guidance and educational resources for the epilepsy community.
This symposium brings together experts to review the evolving therapeutic pipeline and outline key considerations for safe, ethical, and equitable implementation. The session addresses clinical readiness, infrastructure and workforce needs, equitable access to advanced therapies, consent and long-term follow-up, and strategies to support both academic and community practices. The goal is to equip providers and health systems with a practical framework to prepare for the responsible integration of disease-modifying therapies as they approach regulatory approval.
In this symposium, we address the intricacies of the frontal lobe, starting with its anatomy, aura seizure presentation, cognitive/behavioral correlates, genetics/imaging correlates, and surgical approaches for the treatment of frontal lobe epilepsies.